BioStock: Annexin’s CEO: “Our biggest success in a long time”

Annexin reported positive findings in the phase II study with ANXV in retinal vein occlusion, RVO, in August. This justifies the continuation of the study, which now follows a simplified design that is expected to accelerate patient recruitment. CEO Anders Haegerstrand explains more about the significance of the findings and the continued development within RVO in an interview with BioStock.

Read the interview with Annexin Pharmaceuticals' CEO Anders Haegerstrand here:

https://www.biostock.se/en/2023/09/annexins-ceo-our-biggest-success-in-a-long-time/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/